Avi B. Markowitz, MD, FACP
Department of General Oncology, Division of Cancer Medicine
About Avi B. Markowitz
Dr. Avi Markowitz was born in Poughkeepsie, New York and grew up in Virginia and New Jersey. He received his undergraduate degree from Rutgers University in New Brunswick, New Jersey in 1977. He then graduated with an MD from the University of California, San Francisco School of Medicine in 1981. He completed a Residency in Internal Medicine at the University of California, San Diego in 1984. Dr. Markowitz returned to the Cancer Research Institute at the University of California, San Francisco School of Medicine where he completed his Fellowship in Medical Oncology in 1986. After working briefly as a laboratory investigator for Cetus (a biotechnology company later acquired by Chiron), he returned to the University of California, San Francisco School of Medicine as a Clinical Instructor in the Cancer Research Institute. During that time, he began his career as a clinical investigator. In 1987 Dr. Markowitz accepted a Faculty appointment at M. D. Anderson Cancer Center as an Assistant Professor in the Department of Clinical Immunology and Biological Therapy. There, he continued his clinical investigations with a variety of novel biologic agents. He completed his stay at M.D. Anderson in the Department of Gastrointestinal Medical Oncology in 1995.
Dr. Markowitz then moved to Bryan/College Station, Texas where he established two American College of Surgeons accredited Cancer Centers at St. Joseph Regional Medical Center and College Station Medical Center. He was also Director of Research and Development at St. Joseph Regional Cancer Center. In June 2005 Dr. Markowitz was recruited to UTMB as Chief of Hematology/Oncology. Since coming to UTMB he has assumed the roles of Director of the Medical Oncology Fellowship for 5 years. He has been Chair of the Cancer Committee since January 2008 and remains the Associate Medical Director of Experimental Therapeutics in the UTMB Comprehensive Cancer Center where he is also Director of the Oncology Clinical Trials Office which monitors adult clinical oncology research at UTMB. Dr. Markowitz remains interested in novel drug development with a particular interest in targeted therapy and immunotherapy. Clinically, he is interested in the management of patients with chronic leukemia, lymphoma, melanoma, and breast cancer.
Present Title & Affiliation
Primary Appointment
Professor, Department of General Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Galveston, TX
Dual/Joint/Adjunct Appointment
Professor, Department of General Oncology, The University of Texas MD Anderson Cancer Center, Galveston, TX
Professor, Department of General Oncology, The University of Texas Medical Branch, Galveston, TX
Endowed Position-Bill and Louise Bauer Distinguished Chair in Cancer Research, Department of Cancer Medicine, The University of Texas Medical Branch, Galveston, TX
Education & Training
Degree-Granting Education
| 1981 | University of California School of Medicine, San Francisco, California, US, MD |
| 1977 | Rutgers College New Brunswick, New Brunswick, New Jersey, US, Biochemistry, AB |
Postgraduate Training
| 1984-1986 | Research Fellowship, Cancer Research Institute Fellowship, University of California, San Francisco, California |
| 1981-1984 | Clinical Residency, University of California San Diego, San Diego, California |
| 1978-1979 | Research Fellowship, UCSF School of Medicine, San Francisco, California |
Board Certifications
| 2021 | Internal Medicine - NBPS |
| 2021 | Medical Oncology - NBPS |
| 1991 | Medical Oncology - ABIM |
| 1984 | Internal Medicine - AMIM |
Experience & Service
Academic Appointments
Visiting Professor, Department of General Oncology, The University of Texas Medical Branch, Galveston, TX, 2005 - 2005
Assistant Internist, Department of Gastrointestinal (GI) Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 1990 - 1995
Assistant Professor, Department of General Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 1987 - 1995
Assistant Internist, Department of General Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 1987 - 1990
Clinical Instructor, Department of General Oncology, UCSF Cancer Research Institute, San Francisco, CA, 1986 - 1987
Administrative Appointments/Responsibilities
Associate Medical Director, Department of General Oncology, The University of Texas Medical Branch, Galveston, TX, 2009 - 2018
Associate Medical Director, Department of Clinical Cancer Prevention - Research, The University of Texas Medical Branch, Galveston, TX, 2007 - 2009
Clinical Medical Director, Department of General Oncology, The University of Texas Medical Branch, Galveston, TX, 2007 - 2018
Associate Medical Director, Department of General Oncology, The University of Texas Medical Branch, Galveston, TX, 2005 - 2008
Fellowship Program Director, Department of General Oncology, The University of Texas MD Anderson Cancer Center, Galveston, TX, 2005 - 2010
Administrative Director, Department of General Oncology, College Station Medical Center, College Station, TX, 1998 - 2001
Associate Administrative Director, Department of General Internal Medicine - Research, St. Joseph Regional Cancer Center, Bryan, TX, 1995 - 2005
Institutional Committee Activities
Member, UTMB-MD Anderson Medical Oncology Work Group, 2015 - Present
Member, UTMB-Velos Executive Steering Committee, 2013 - Present
Member, Council of Lead Investigators, CTNeT (Statewide Clinical Trials Network of Texas), 2012 - 2013
Member, Board of Directors, Association of Clinical Researchers and Educators, 2009 - Present
Member, Steering Committee, Association of Clinical Researchers and Educators, 2009 - Present
Member, UTMB Cancer Center Day Planning Committee, 2009 - 2009
Member, Southwest Oncology Group Board of Governors, 2008 - 2010
Member, UTMB Pain Medicine Fellowship Multidisciplinary Committee, 2008 - Present
Member, UTMB Quality of Care Committee, 2008 - 2011
Chair, UTMB Cancer Committee, 2008 - Present
Member, UTMB School Cancer Center Membership Committee, 2007 - Present
Member, UTMB Cancer Patient Acceptance Committee, 2006 - Present
Member, UTMB Community Physician Partnerships Committee, 2006 - 2007
Member, Faculty Group Practice Executive Committee, 2006 - 2007
Member, UTMB Faculty Group Practice Executive Committee, 2006 - 2007
Member, UTMB Special Task Force for Interventional Radiology Section in the Department of Radiology and the Department of Medical Management, 2006 - 2007
Member, UTMB Joint Clinical Enterprise Research and Education Committee, 2005 - 2007
Member, UTMB Search Committee for Chairman of Department of Radiology, 2005 - 2007
Member, UTMB Pharmacy & Therapeutics Committee, 2005 - Present
Member, UTMB Cancer Committee, 2005 - Present
Member, Graduate Medical Education Committee, 2005 - 2010
Member, Council of Full Professors, 2005 - Present
Member, CPRIT (Cancer Prevention and Research Institute of Texas)- Clinical Trials Working Group, 2000 - 2012
Board of Directors, University of California, San Francisco Cancer Biotherapy Research Group, 1998 - 2000
Member, St. Joseph Regional Cancer Center Blood Usage Review Committee, 1997 - 2005
Chairman, St. Joseph Regional Cancer Center Pharmacy and Therapeutics Committee, 1997 - 2005
Chairman, College Station Medical Center Cancer Committee, 1997 - 2001
Member, College Station Medical Center Cancer Committee, 1997 - 2005
Cancer Liaison Physician of the Commission on Cancer, University of California, San Francisco American College of Surgeons, 1997 - 2000
Member, Texas Medical Foundation Health Quality Institute, 1995 - Present
Member, St. Joseph Regional Cancer Center Cancer Committee, 1995 - 2005
Member, St. Joseph Regional Cancer Center Pharmacy and Therapeutics Committee, 1995 - 2005
Director, St. Joseph Regional Cancer Center Tumor Conference, 1995 - 2005
Member, University of California San Francisco National Melanoma Faculty, 1995 - 2005
Member, University of California San Francisco Steering Committee, American Cancer Society, Brazos County, 1995 - 2005
Member, University of California San Francisco General Oncology Clinic, 1994 - 2005
Chairman, MD Anderson Cancer Center Clinical Pertinence Subcommittee, 1993 - 1995
Member, MD Anderson Medical Records Committee, 1993 - 1995
Member, MD Anderson Desktop Information Standards Task Force, 1993 - 1995
National Faculty Member, University of California San Francisco Consultant Care Network, 1993 - 1994
Vice-Chairman, MD Anderson Pharmacy and Therapeutics Committee, 1992 - 1995
Member, MD Anderson Database Master Plan Committee, 1992 - 1994
Member, MD Anderson Computer Based Patient Record Steering Committee, 1992 - 1995
Member, MD Anderson Pharmacy and Therapeutics Committee, 1991 - 1995
Expert Panel, University of California San Francisco Cancer Research Institute Grand Rounds (Twice Yearly), 1991 - 2005
Member, MD Anderson Research Medical Library Advisory Committee, 1991 - 1993
Chairman, MD Anderson SMS Computerization Committee, 1990 - 1992
Member, MD Anderson Surveillance Committee, 1990 - 1994
Member, MD Anderson Utilization Committee, 1990 - 1991
Vice-Chairman, MD Anderson Medical Records Committee, 1989 - 1991
Member, MD Anderson Medical Records Committee, 1988 - 1991
Attending Oncologist, University of California San Francisco Biologic Response Modifiers Clinic, 1986 - 1987
Attending Oncologist, University of California San Francisco Gynecologic Oncology Tumor Board, 1986 - 1987
Attending Oncologist, University of California San Francisco Head and Neck Tumor Board, 1986 - 1987
Attending Oncologist, University of California San Francisco General Oncology Clinic, 1986 - 1987
Member, University of California San Francisco Gynecologic Oncology Tumor Board, 1984 - 1987
Member, University of California San Francisco Cancer Research Institute Grand Rounds (Twice Yearly), 1984 - 1987
Member, University of California San Francisco Professional Education Committee, ACS, California Division, 1984 - 1987
Honors & Awards
| Phi Beta Kappa: Rutgers College | |
| President's Undergraduate Fellow: UCSF School of Medicine | |
| Physician of the Year: American Cancer Society, Brazos County | |
| Fellow, American College of Physicians | |
| Best Doctors in America | |
| Best Doctors in Houston | |
| Doctor of Excellence |
Selected Publications
Peer-Reviewed Articles
- Weiser R, Polychronopoulou E, Haque W, Hatch SS, He J, Qiu S, Markowitz A, Gradishar WJ, Kuo YF, Klimberg VS. Prognosis and Chemotherapy Use in Breast Cancer Patients with Multiple Lymphatic Micrometastases: An NCDB Analysis. Ann Surg Oncol 28(13):8717-8727, 2021. e-Pub 2021. PMID: 34250555.
- Al Asad O, Salam A, Mannem S, Ninan M, Markowitz A, Jana B. Alternative therapy for Epstein Barr virus related hemophagocytic lymphohistiocytosis. Case Rep Oncol None(None):None, 2015. PMID: None.
- Mesia R, Henke M, Fortin A, Minn H, Ancona ACY, Cmelak A, Markowitz AB, Hotte SJ, Singh S, Chan ATC, Merlano MC, Skladowski K, Zhang A, Oliner KS, VanderWalde A, Giralt J. Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): a randomized, controlled, open-label phase 2 trial. Lancet Oncology 16(2):208-220, 2015. PMID: None.
- Peguero JA, Khanfar A, Mannem S, Willis M, Markowitz A. Impending carotid blow out syndrome. J Clin Oncol None(None):None, 2014. PMID: None.
- Koshy J, Alperin J, Jana B, Markowitz A, Y-W Q. A case of Philadelphia chromosome positive myeloproliferative neoplasm in a pregnant woman with unusual primary myelofibrosis features. Case Reports in Hematology None(None):None, 2013. PMID: None.
- Ghadimi-Mahani M, McDonnold MA, Jana B, Markowitz A, Willis M, Harirah H. Sarcomatoid carcinoma of the oral cavity during pregnancy. None None(None):None, 2013. PMID: None.
- Abdulla NA, Ninan MJ, Markowitz AB. Rituximab: Current status as therapy for malignant and benign hematologic disorders. BioDrugs 26(2):71-82, 2012. PMID: None.
- Weber MA, Black HR, Fonseca R, Garber J, Gonzalez-Campoy JM, Kimmelstiel C, Markowitz AB, Nakayama D, Stell LK, Stossel TP. Association of clinical researchers and educators :A statement on relationships between physicians and industry. Endocrine Practice 18(6):1029-1037, 2012. PMID: None.
- Gopal M, Abdulla N, Elghetany M, Markowitz A, McClain K. Epstein-Barr virus associated hemophagocytic lymphohistiocytosis: Case report with unusual clinical features with brief review of literature. J Malign Tumours 1(None):60-67, 2011. PMID: None.
- Bhutani MS, Saftiou A, Chaya C, Gupta P, Markowitz AB, Willis M, Kessel I, Sharma G, Zwischenberger JB. Irregular echogenic foci representing coagulation necrosis: a useful but perhaps under-recognized EUS echo feature of malignant lymph node invasion. J Gastrointestin Liver Dis 18(2):181-184, 2009. PMID: None.
- Wang J, Yong FK, Freeman J, Markowitz AB, Goodwin JS. Temporal trends and predictors of perioperative chemotherapy use in elderly patients with resected non small cell lung cancer. Cancer 112(2):382-390, 2008. PMID: None.
- Bidyasar S, Montoya M, Suleman K, Markowitz AB. Sweet syndrome associated with granulocyte colony-stimulating factor. J Clin Oncol:4355-4356, 2008. PMID: None.
- Reddy NK, Markowitz AB, Abbruzzese JL, Bhutani MS. Knowledge of indications and utilization of EUS: a survey of oncologists in the USA. J Clin Gastroenterol:892-896, 2008. PMID: None.
- Rao N, Sanguineti G, Chaljub G, Newlands S, Markowitz A, Pena J. Neck levels that are negative on initial CT do not need to be dissected. International Journal of Radiation Oncology Biology Physics None(None):None, 2006. PMID: None.
- Vaughn DJ, Broome CM, Hussain M, Gutheil JC, Markowitz AB. Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer. J Clin Oncol 20(None):937-940, 2002. PMID: None.
- Ravandi-Kashani F, Cortes J, Cohen P, Talpaz M, O’Brien S, Markowitz A, Kantarjian H. Cutaneous ulcers associated with hydroxyurea therapy in myeloproliferative disorders. Leuk Lymphoma 35 35(None):109-18, 1999. PMID: None.
- Khuri FR, Fossella FV, Lee JS, Murphy WK, Shin DM, Markowitz AB, Glisson BS. Phase II trial of recombinant interferon alfa-2a with etoposide/cisplatin induction and interferon/megestrol acetate maintenance in extensive small cell lung cancer. J Interferon and Cytokine Res 18:241-45, 1998. PMID: None.
- Patt YZ, Jones DV, Hoque A, Lozano R, Markowitz A, Raijman I, Lynch P, Charnsangavej C. Phase II trial of intravenous fluorouracil and subcutaneous interferon alfa-2b for biliary tract cancer. J Clin Oncol 14(None):2311-2315, 1996. PMID: None.
- Jones DV, Lozano R, Hoque A, Markowitz A, Patt YZ. Phase II study of paclitaxel therapy for unresectable biliary tree carcinomas. J Clin Oncol None(14):2306-2310, 1996. PMID: None.
- Jones DV, Sugarman SM, Markowitz AB, Levin B, Abbruzzese JL, Evans DB, Charnsangavej C, Smith R, Patt YZ. Cisplatin, 5-fluorouracil, and leucovorin in the therapy of adenocarcinomas of the pancreas. Oncology Reports 2:1121-1123, 1995. PMID: None.
- Pazdur R, Bready B, Ajani JA, Abbruzzese JL, Markowitz A, Sugarman S, Jones D, Levin B. Phase II trial of isotretinoin and recombinant interferon alfa-2a in metastatic colorectal carcinoma. Am J Clin Oncol 18(None):436-438, 1995. PMID: None.
- Pazdur R, Lassere Y, Rhodes V, Ajani JA, Sugarman SM, Patt YZ, Jones DV, Markowitz AB, Abbruzzese J, Bready B, Levin B. Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma. J Clin Oncol 12:2296-2300, 1994. PMID: None.
- Kurzrock R, Cohen PR, Markowitz A. Clinical manifestations of vasculitis in patients with solid tumors: A case report and review of the literature. Arch Int Med 154(None):334-340, 1994. PMID: None.
- Kirk IR, Carrasco CH, Lawrence DD, Chuang VP, Richli WR, Charnsangavej C, Kavanagh JJ, Kudelka AP, Freedman RS, Markowitz AB. Intraperitoneal catheters: Percutaneous placement with fluoroscopic guidance. JVIR:299-304, 1993. PMID: None.
- Danhauser LL, Freimann JH, Gilchrist TL, Gutterman JU, Hunter CY, Yeomans AC, Markowitz AB. Phase I and plasma pharmacokinetic study of infusional 5-fluorouracil combined with recombinant interferon alfa-2b in patients with advanced cancer. J Clin Oncol:751-761, 1993. PMID: None.
- Wetzler M, Estrov Z, Talpaz M, Markowitz A, Gutterman JU, Kurzrock R. Granulocyte-macrophage colony-stimulating factor as a cause of paraneoplastic leukemoid reaction in advanced transitional cell carcinoma. J Int Med 234(None):417-420, 1993. PMID: None.
- Estrov Z, Markowitz AB, Kurzrock R, Wetzler M, Kantarjian HM, Ferrajoli A, Gutterman JU, Talpaz M. M. Suppression of chronic myelogenous leukemia colony growth by interleukin-4. Leukemia. Leukemia 7:214-220, 1993. PMID: None.
- Dimopoulos MA, Logothetis CJ, Markowitz A, Sella A, Amato R, Ro J. Collecting duct carcinoma of the kidney. Brit J Urol None(None):388-391, 1993. PMID: None.
- Ajani JA, Abbruzzese JL, Markowitz AB, Patt YZ, Daugherty K. Phase II study of etoposide and alpha-interferon in patients with advanced measurable colorectal carcinoma. Invest New Drugs 11:67-69, 1993. PMID: None.
- Sella, Swanson DA, Ro JY, Putnam JB, Amato RJ, Markowitz AB, Logothetis CJ. Surgery following response to interferon--based therapy for residual renal cell carcinoma. J Urol 149(None):19-22, 1993. PMID: None.
- Schilling P, Murray JL, Markowitz AB. Novel tumor necrosis factor toxic effects: Pulmonary hemorrhage and severe hepatic dysfunction. Cancer 69:256-60, 1992. PMID: None.
- Itoh K, Balch CM, Murray JL, Parkinson DR, Markowitz AB, Talpaz M, Lee K, Zukiwski AA, Ross MI, Legha SS, Hayakawa K, Salmeron MA, Augustus LB. Immunological properties of melanoma tumor-infiltrating lymphocytes before and after IL-2-based biotherapies. Vivo 5:647-654, 1991. PMID: None.
- Freimann JH, Markowitz AB. Cytokines and chemotherapy: A new approach to therapy for solid tumors. Cancer Bull:224-232, 1991. PMID: None.
- Hayakawa K, Salmeron MA, Parkinson DR, Markowitz AB, von Eschenbach AC, Legha SS, Balch CM, Ross MI, Augustus LB, Itoh K. Immunological study of interleukin-2 activated tumor-infiltrating lymphocytes for adoptive cellular therapy for human metastatic melanoma and renal cell carcinoma. J Immunother 10(None):None, 1991. PMID: None.
- Neefe JR, Legha SS, Markowitz A, Salmon S, Meyskens F, Groopman J, Campion M, Evans L. Phase II study of recombinant - interferon in malignant melanoma. Am J Clin Oncol 13(None):None, 1990. PMID: None.
- Hudson MM, Markowitz AB, Gutterman JU, Knowles RD, Snyder JS, Kleinerman ES. Effect of recombinant human interleukin 4 on human monocyte activity. Cancer Res 50:3154-3158, 1990. PMID: None.
- Parkinson DR, Talpaz M, Lee KH, Legha S, Markowitz AB, Itoh K, Balch CM, Murray JL, Zukiwski AA, Benjamin RS, Gutterman JU. Interleukin-2 alone and in combination with other cytokines in melanoma: The investigational approach at the University of Texas M. D. Anderson Cancer Center. Cancer Treat Rev 16:39-48, 1989. PMID: None.
- Dutcher JP, Creekmore S, Weiss GR, Margolin K, Markowitz AB, Roper MA, Parkinson D, Ciobanu N, Fisher RI, Boldt DH, Doroshow JH, Rayner AA, Hawkins M, Atkins M. A phase II study of interleukin-2 and lymphokine activated killer (LAK) cells in patients with metastatic malignant melanoma. J Clin Oncol 4:477-485, 1989. PMID: None.
Other Articles
- Nelson BE, Hong A, Okereke I, Markowitz A, Willis M, Muthukumarana PV, Nawgiri R Non-neoplastic inflammatory pseudotumor of the lung after immunotherapy for melanoma: A diagnostic pitfall on fine needle aspiration biopsy of lung. Diagn Cytopathol 49(10):1150-1154, 2021. PMID: 34331523.
Abstracts
- Johnson P, Zatarain JR, Mrazek AA, Hellmich J, Gajjar A, Orihuela E, Sonstein J, Silva HC, Markowitz AB, Szabo C, Hellmich MR, Druzhyna N, Zhao Y, Chao C. Urine thiosulfate level is not a reliable biomarker to diagnose prostate or breast cancers. Proc South Texas Chapter Amer Coll Sur, 2015. PMID: None.
- Giralt J, Fortin A, Mesia R, Minn H, Henke M, Ancona A, Cmelak A, Markowitz A, Hotte S, Singh S, Chan A, Merlan M, Zhang A, Oliner K, VanderWalde A. A phase II, randomized trial (CONCERT-1) of chemoradiotherapy (CRT) with or without panitumumab (pmab) in patients (pts) with unresected, locally advanced squamous cell carcinoma of the head and neck (LASCCHN). Proc Am Soc Clin Oncol None(None):None, 2012. PMID: None.
- Cox JA, Eltorky MA, Wolski MJ, Sturgeon JD, Joyner MM, Markowitz AB, Hatch SS. Pleomorphic lobular breast carcinoma: A review of 35 cases at a single institution. Proc Am Soc Clin Oncol 175(None):None, 2011. PMID: None.
- Katta SF, Malani AK, Rodgers HA, Willis M, Markowitz AB. A phase II study of arsenic trioxide (ATO) in patients with advanced hepatocellular carcinoma (HCC). Proc Am Soc Clin Oncol 28(None):None, 2010. PMID: None.
- Giralt J, Trigo JM, Nuyts S, Ozsahin M, Markowitz AB, Daisne J, Skladowski K, Lonchay C, Holeckova P, Smitt M. A phase 2 randomized trial of radiotherapy (RT) plus panitumumab compared to chemoradiotherapy in patients with unresected, locally advanced squamous cell carcinoma of the head and neck (SCCHN): interim pooled safety analysis. European Journal of Cancer Supplements 7(2), 2009. PMID: None.
- Montoya ME, Markowitz AB, Klementich F, Palacio D. Docetaxel and fluid retention: Use of single-dose dexamethasone. Proc Am Soc Clin Oncol 25, 2007. PMID: None.
- Gupta P, Tarcin O, Zwischenberger JB, Chaya C, Willis M, Markowitz AB, Kessel IL, Sharma G, Bhutani M. Utility of JAVA based software for computer-aided EUS differentiation of benign and malignant lymph nodes in lung cancer. Am J Gastroenterol, 2007. PMID: None.
- Patt YZ, Hoque A, Jones D, Markowitz A. Phase II trial of cisplatinum, 5-FU, and leucovorin (PFL) for primary duodenal carcinoma (PDC). Proc Am Soc Clin Oncol 14(None):None, 1995. PMID: None.
- Hoque A, Chase J, Lozano R, Markowitz A, Jones DV, Carrasco H, Roh MS, Curley SA, Patt YZ. Educating patients on hepatic arterial infusion (HAI) as an option for treatment of hepatocellular carcinoma (HCC) and colorectal cancer metastatic to the liver. J Cancer Ed None(None):None, 1995. PMID: None.
- Patt YZ, Jones D, Markowitz A. Phase II trial of 5-FU and alpha-interferon in biliary tract cancers (BT). Proc Am Soc Clin Oncol None(None):None, 1995. PMID: None.
- Abbruzzese JL, Evans D, Gravel D, Markowitz A, Patt Y, Pazdur R. Docetaxel (D), a potentially active agent for patients with pancreatic adenocarcinomas. Proc Am Soc Clin Oncol None(None):None, 1995. PMID: None.
- Sugarman SM, Pazdur R, Brown C, Vosika GJ, Jones DV, Markowitz A, Ajani JA, Bready B, Soo E, Levin B. A phase II trial of Immther for previously untreated patients (pts) with metastatic colorectal cancer (CRC) to the liver. Proc Am Soc Clin Oncol None(13):None, 1994. PMID: None.
- Markowitz A, Thielvoldt D, Patt Y, Sugarman S, Jones D, Pazdur R, Abbruzzese J, Levin B. Prolonged continuous intravenous infusion (CIVI) fluorouracil (5-FU) plus daily subcutaneous (sc) interferon-a2b (IFN) has activity in patients (pts) with colorectal cancer (CRC) who have failed prior 5-FU: results of a phase I-II study. Proc Am Soc Clin Oncol 13(None):None, 1994. PMID: None.
- Jones DV, Jr, Sugarman S, Markowitz A, Levin B, Abbruzzese JL, Patt YZ. A phase I-II study of amiodarone (AM) and doxorubicin (DOX) for patients (pts) with advanced colorectal cancer (CRC). Proc Am Soc Clin Oncol 13(None):None, 1994. PMID: None.
- Markowitz A, Mavligit G, Thielvoldt D. Phase I study of hepatic arterial infusion (HAI) of interleukin-4 (IL-4). Proc Am Assoc Can Res 35(None):None, 1994. PMID: None.
- Markowitz AB. Interleukin-4 (IL-4) in cancer and bone marrow failure. Cancer Investigation, 1994. PMID: None.
- Pazdur R, Rhodes V, Lassere Y, Bready B, Soo E, Ajani JA, Abbruzzese JL, Sugarman S, Jones D, Markowitz A, Ho D, Levin B. UFT plus leucovorin: a potentially effective oral regimen in colorectal carcinoma. Proc Am Soc Clin Oncol 13(None):None, 1994. PMID: None.
- Glisson BS, Palmer JL, Shin DM, Wester M, Markowitz AB. Phase II trial of interferon alfa (IFN) + etoposide/cisplatin (EP) induction and IFN/Megace (M) maintenance in extensive small cell lung cancer (ESCLC). Proc Am Soc Clin Oncol 12, 1993. PMID: None.
- Markowitz AB, Thielvoldt D. Intracavitary interferon-2b is highly active against malignant effusions. Proc Am Assoc Can Res 34, 1993. PMID: None.
- Glisson BS, Markowitz AB, Mortensen T. Phase II trial of etoposide (E)/cisplatin (P)/interferon alpha (IFN) induction and interferon alpha/megace (M) maintenance in extensive small cell lung cancer (ESCLC). Proc Am Soc Clin Oncol 11(None):None, 1992. PMID: None.
- Markowitz A, Thielvoldt D, Yeomans A, Levin B, Hunter C, Gutterman J. Phase I study of intraperitoneal (IP) interferon- (IFN-) and tumor necrosis factor (TNF) in patients (PTS) with advanced intra-abdominal cancer. Proc Am Soc Clin Oncol 11(None):None, 1992. PMID: None.
- Markowitz A, Thielvoldt D, Yeomans A, Rubenstein E, Escalante C, Freimann J, Hunter C, Gutterman J. A phase I study of patients (PTS) with ascites (A) or pleural effusion (PE). Proc Am Soc Clin Oncol 11(None):None, 1992. PMID: None.
Selected Presentations & Talks
Local Presentations
- 2016. Emerging perspectives in hematologic malignancies. Invited. Baylor University Medical Oncology Grand Rounds. Houston, TX, US.
- 2016. Oncology and Texas Department of Correctional Care. Invited. UTMB School of Medicine. Galveston, TX, US.
- 2015. Cancer: The new chronic illness. UTMB 24th Annual Essentials in Internal Medicine: Update on Principles and Practice. Invited. UTMB. Galveston, TX, US.
- 2014. Cancer: The new chronic illness. Invited. 7th Academic and Health Policy Conference on Correctional Health (Special Session). Houston, TX, US.
Regional Presentations
- 2016. Cancer: The New Chronic Illness. Correctional Managed Healthcare Meeting. Invited. Frontiers of Flight Museu. Dallas, TX, US.
- 2015. Cancer: The New Chronic Illness. Invited. Robert E. Askew, Sr., MD Cancer Symposium. Austin, TX, US.
- 2014. Gazyva (obinutuzumab) for chronic lymphocytic leukemia. Invited. Arlington Cancer Center. Arlington, TX, US.
- 2013. Novel therapies for cancer treatment. Invited. The State of Texas Correctional Managed Health Care Committee. Frontiers of Flight Museum. Dallas, TX, US.
National Presentations
- 2017. Emerging perspectives in hematologic malignancies. Invited. 2017 Genentech National Sales Meeting. Las Vegas, NV, US.
- 2016. Emerging perspectives in hematologic malignancies. Invited. Emerging perspectives in hematologic malignancies. Augusta, GA, US.
- 2016. Emerging perspectives in hematologic malignancies. Invited. Emerging perspectives in hematologic malignancies. South Lacrosse, WI, US.
- 2016. Emerging perspectives in hematologic malignancies. Invited. UCLA Olive View Medical Center. Sylmar, CA, US.
- 2016. Emerging perspectives in hematologic malignancies. Invited. Emerging perspectives in hematologic malignancies. San Juan, PR, US.
- 2015. Molecular basis of hematologic malignancies. Invited. Tulsa, OK, US.
- 2015. Key opinion leader presentation for Genentech Hematology. Invited. Key opinion leader presentation for Genentech Hematology. Phoenix, AZ, US.
- 2015. Molecular basis of hematologic malignancies. Invited. Cancer Care Associates of York. York, PA, US.
- 2015. Molecular basis of hematologic malignancies. Invited. Cancer Treatment Centers of America. Tulsa, OK, US.
- 2015. Molecular basis of hematologic malignancies. Invited. Molecular basis of hematologic malignancies. Lousiville, KY, US.
- 2015. Hematology Core Training Class: CLL and Indolent NHL. Invited. Hematology Core Training Class: CLL and Indolent NHL. San Francisco, CA, US.
- 2014. Synribo (omacetaxine mepesuccinate) for injection, for subcutaneous use. Invited. Synribo (omacetaxine mepesuccinate) for injection, for subcutaneous use. San Francisco, CA, US.
- 2014. Targeted Anti CD-20 Therapies: Treatments in NHL and CLL. Invited. Targeted Anti CD-20 Therapies: Treatments in NHL and CLL. Omaha, NE, US.
- 2014. Synribo (omacetaxine mepesuccinate) for injection, for subcutaneous use. Invited. Synribo (omacetaxine mepesuccinate) for injection, for subcutaneous use. Chicago, IL, US.
- 2014. Synribo (omacetaxine mepesuccinate) for injection, for subcutaneous use. ION In-Practice Presentation: Emerald Coast Cancer Center. Invited. Emerald Coast Cancer Center. Fort Walton Beach, FL, US.
- 2014. Treanda (Bendamustine): A unique treatment for patients with non-Hodgkin lymphoma (NHL). Invited. St. Joseph's Hospital. Patterson, NJ, US.
- 2014. Synribo (omacetaxine mepesuccinate) for injection, for subcutaneous use. Invited. Woodlands Medical Specialists. Pensacola, FL, US.
- 2014. Targeted Anti CD-20 Therapies: Treatments in NHL and CLL. Invited. St. John West Shore Tumor Conference. Westlake, OH, US.
- 2014. Synribo (omacetaxine mepesuccinate) for injection, for subcutaneous use. Invited. Synribo (omacetaxine mepesuccinate) for injection, for subcutaneous use. Austin, TX, US.
- 2014. Treanda (Bendamustine): A unique treatment for patients with non-Hodgkin lymphoma (NHL). Invited. Treanda (Bendamustine): A unique treatment for patients with non-Hodgkin lymphoma (NHL). Brownsville, TX, US.
- 2014. Targeted Anti CD-20 Therapies: Treatments in NHL and CLL. Invited. Targeted Anti CD-20 Therapies: Treatments in NHL and CLL. Avon, OH, US.
- 2014. Targeted Anti CD-20 Therapies: Treatments in NHL and CLL. Invited. Targeted Anti CD-20 Therapies: Treatments in NHL and CLL. Dallas, TX, US.
- 2014. Targeted Anti CD-20 Therapies: Treatments in NHL and CLL. Invited. Targeted Anti CD-20 Therapies: Treatments in NHL and CLL. Santa Fe, NM, US.
- 2014. Targeted Anti CD-20 Therapies: Treatments in NHL and CLL. Invited. Targeted Anti CD-20 Therapies: Treatments in NHL and CLL. Webster, TX, US.
- 2014. Targeted Anti CD-20 Therapies: Treatments in NHL and CLL. Invited. Targeted Anti CD-20 Therapies: Treatments in NHL and CLL. Albuquerue, NM, US.
- 2014. Chronic Lymphocytic Leukemia. ION-in-Practice presentation. Invited. Central Park Hematology and Oncology. New York, NY, US.
- 2014. Granix (G-CSF). Invited. Warner Robbins, GA, US.
- 2014. Gazyva (obinutuzumab) for chronic lymphocytic leukemia. Invited. Oncology Nurses of Central Oklahoma (Oncology Nursing Society). Oklahoma City, OK, US.
- 2014. Granix (G-CSF). Invited. Philadelphia, PA, US.
- 2014. Gazyva (obinutuzumab) for chronic lymphocytic leukemia. Invited. Cancer Centers of Southwest Oklahoma. Lawton, OK, US.
- 2014. Gazyva (obinutuzumab) for chronic lymphocytic leukemia. Invited. Gazyva (obinutuzumab) for chronic lymphocytic leukemia. Houston, TX, US.
- 2014. Gazyva (obinutuzumab) for chronic lymphocytic leukemia. Invited. Gazyva (obinutuzumab) for chronic lymphocytic leukemia. Dayton, OH, US.
- 2013. Gazyva (obinutuzumab) for chronic lymphocytic leukemia. Invited. ASH. New Orleans, LA, US.
- 2013. Treanda (Bendamustine): A unique treatment for patients with non-Hodgkin lymphoma (NHL). Invited. Treanda (Bendamustine): A unique treatment for patients with non-Hodgkin lymphoma (NHL). Minneapolis, MN, US.
- 2013. Treanda (Bendamustine): A unique treatment for patients with chronic lymphocytic leukemia (CLL). ION In-Practice Presentation. Invited. North Memorial Healthcare/Hubert H. Humphrey Cancer Center. Robbinsdale, MN, US.
- 2013. Overview of CLL and Rituxan in combination with FC for previously untreated and previously treated CLL. Invited. Northeast Oklahoma Oncology Nursing Society. Tulsa, OK, US.
- 2013. First-line management strategies for follicular or low-grade NHL. Invited. First-line management strategies for follicular or low-grade NHL. Tulsa, OK, US.
- 2013. Focusing on the expectations of a thought leader from a key opinion leader perspective. Invited. Fourth Key Opinion Leader Relationship Summit. Philadelpha, PA, US.
- 2013. Synribo (omacetaxine mepesuccinate) for injection, for subcutaneous use. Invited. Synribo (omacetaxine mepesuccinate) for injection, for subcutaneous use. San Antonio, TX, US.
- 2013. Fourth Key Opinion Leader Relationship Summit. Invited. Philadelphia, PA, US.
- 2013. Using Synribo (omacetaxine mepesuccinate) for injection, for subcutaneous use. Invited. Using Synribo (omacetaxine mepesuccinate) for injection, for subcutaneous use. Chicago, IL, US.
- 2013. Synribo (omacetaxine mepesuccinate) for injection, for subcutaneous use. Invited. Synribo (omacetaxine mepesuccinate) for injection, for subcutaneous use. Chicago, IL, US.
- 2013. Synribo (omacetaxine mepesuccinate) for injection, for subcutaneous use. Invited. Synribo (omacetaxine mepesuccinate) for injection, for subcutaneous use. Tulsa, OK, US.
- 2013. Treanda (Bendamustine): A unique treatment for patients with non-Hodgkin lymphoma (NHL). Invited. Treanda (Bendamustine): A unique treatment for patients with non-Hodgkin lymphoma (NHL). Denver, CO, US.
- 2013. Synribo (omacetaxine mepesuccinate) for injection, for subcutaneous use. Invited. Arlington Cancer Center, US.
- 2012. Lymphoma and Related Disorders II. DHM Second Year Medical Student Lecture. UTMB School of Medicine. Invited. Lymphoma and Related Disorders II. DHM Second Year Medical Student Lecture. UTMB School of Medicine. Galveston, TX, US.
- 2012. Problem Based Learning: Chronic Lymphocytic Leukemia Roundtable. Invited. Bay Pines VA Hospital. St. Petersburg, FL, US.
- 2012. First-line management strategies for follicular or low-grade NHL. Invited. Barberton Hospital Oncology Tumor Conference. Barberton, OH, US.
- 2012. Treanda (Bendamustine): A unique treatment for patients with chronic lymphocytic leukemia (CLL). ION In-Practice Presentation. Invited. Treanda (Bendamustine): A unique treatment for patients with chronic lymphocytic leukemia (CLL). ION In-Practice Presentation. Youngstown, OH, US.
- 2012. Treanda (Bendamustine): A unique treatment for patients with chronic lymphocytic leukemia (CLL). Invited. Treanda (Bendamustine): A unique treatment for patients with chronic lymphocytic leukemia (CLL). Baltimore, MD, US.
- 2012. Treanda (Bendamustine): A unique treatment for patients with chronic lymphocytic leukemia (CLL). Invited. Treanda (Bendamustine): A unique treatment for patients with chronic lymphocytic leukemia (CLL). Sugarland, TX, US.
- 2012. Treanda (Bendamustine): A unique treatment for patients with chronic lymphocytic leukemia (CLL). ION In-Practice Presentation. Utah Hematology/Oncology. Invited. Treanda (Bendamustine): A unique treatment for patients with chronic lymphocytic leukemia (CLL). ION In-Practice Presentation. Utah Hematology/Oncology. Ogden, UT, US.
- 2011. Treanda (Bendamustine): A unique treatment for patients with chronic lymphocytic leukemia (CLL). Invited. Treanda (Bendamustine): A unique treatment for patients with chronic lymphocytic leukemia (CLL). Austin, TX, US.
- 2011. Treanda (Bendamustine): A unique treatment for patients with chronic lymphocytic leukemia (CLL). Invited. Northwest Cancer Center. Houston, TX, US.
- 2011. Treanda (Bendamustine): A unique treatment for patients with chronic lymphocytic leukemia (CLL). ION In-Practice Presentation: Southeast Nebraska Cancer Center. Invited. Treanda (Bendamustine): A unique treatment for patients with chronic lymphocytic leukemia (CLL). ION In-Practice Presentation: Southeast Nebraska Cancer Center. Lincoln, NE, US.
- 2011. Treanda (Bendamustine): A unique treatment for patients with chronic lymphocytic leukemia (CLL). ION In-Practice Presentation. Invited. Treanda (Bendamustine): A unique treatment for patients with chronic lymphocytic leukemia (CLL). ION In-Practice Presentation. Tulsa, OK, US.
- 2011. Treanda (Bendamustine): A unique treatment for patients with chronic lymphocytic leukemia (CLL). ION In-Practice Presentation. Invited. Treanda (Bendamustine): A unique treatment for patients with chronic lymphocytic leukemia (CLL). ION In-Practice Presentation. Monterey, CA, US.
- 2011. Rituxan Advisory Initiative: Moderator for Rituxan Hematology Multidisciplinary Hospital Advisory Board. Invited. Rituxan Advisory Initiative: Moderator for Rituxan Hematology Multidisciplinary Hospital Advisory Board. New York, NY, US.
- 2011. Treanda (Bendamustine): A unique treatment for patients with chronic lymphocytic leukemia (CLL). ION In-Practice Presentation. Invited. Treanda (Bendamustine): A unique treatment for patients with chronic lymphocytic leukemia (CLL). ION In-Practice Presentation. Birmingham, AL, US.
- 2011. Maximizing Outcomes From Thought Leader Relationships. Panel Discussion: Working with industry partners and implications of the Sunshine act. Invited. Maximizing Outcomes From Thought Leader Relationships. Panel Discussion: Working with industry partners and implications of the Sunshine act. Boston, MA, US.
- 2011. Treanda (Bendamustine): A unique treatment for patients with chronic lymphocytic leukemia (CLL). ION In-Practice Presentation. Sanford Hematology and Oncology. Invited. Treanda (Bendamustine): A unique treatment for patients with chronic lymphocytic leukemia (CLL). ION In-Practice Presentation. Sanford Hematology and Oncology. Sioux Falls, SD, US.
- 2011. Treanda (Bendamustine): A unique treatment for patients with chronic lymphocytic leukemia (CLL). Cancer Clinics of Excellence. Invited. Treanda (Bendamustine): A unique treatment for patients with chronic lymphocytic leukemia (CLL). Cancer Clinics of Excellence. Olympia, WA, US.
- 2011. Treanda (Bendamustine): A unique treatment for patients with chronic lymphocytic leukemia (CLL). ION In-Practice Presentation. Invited. Treanda (Bendamustine): A unique treatment for patients with chronic lymphocytic leukemia (CLL). ION In-Practice Presentation. Birmingham, AL, US.
- 2011. Treanda (Bendamustine): A unique treatment for patients with chronic lymphocytic leukemia (CLL). Invited. Treanda (Bendamustine): A unique treatment for patients with chronic lymphocytic leukemia (CLL). El Paso, TX, US.
- 2011. Problem Based Learning: Chronic Lymphocytic Leukemia Roundtable. Invited. Problem Based Learning: Chronic Lymphocytic Leukemia Roundtable. Fort Myers, FL, US.
- 2011. Treanda (Bendamustine): A unique treatment for patients with chronic lymphocytic leukemia (CLL). ION In-Practice Presentation. Cancer Center Associates. Invited. Treanda (Bendamustine): A unique treatment for patients with chronic lymphocytic leukemia (CLL). ION In-Practice Presentation. Cancer Center Associates. McKinney, TX, US.
- 2011. Treanda (Bendamustine): A unique treatment for patients with chronic lymphocytic leukemia (CLL). ION In-Practice Presentation. Invited. Treanda (Bendamustine): A unique treatment for patients with chronic lymphocytic leukemia (CLL). ION In-Practice Presentation. Findlay, OH, US.
- 2011. Treanda (Bendamustine): A unique treatment for patients with indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within 6 months of a rituximab containing regimen.ION In-Practice Presentation. Invited. Good Samaritan Medical Center. Johnstown, PA, US.
- 2011. Problem Based Learning: Chronic Lymphocytic Leukemia Roundtable. Invited. Community Health Partners Cancer Tumor Board. Lorain, OH, US.
- 2011. First-line management strategies with Rituxan (rituximab): Rituxan with CVP for patients with follicular NHL. Rituxan following CVP for patients with low-grade NHL. Rituxan as maintenance therapy following Rituxan with chemotherapy. Invited. First-line management strategies with Rituxan (rituximab): Rituxan with CVP for patients with follicular NHL. Rituxan following CVP for patients with low-grade NHL. Rituxan as maintenance therapy following Rituxan with chemotherapy. Cleveland, OH, US.
- 2011. Treanda (Bendamustine): A unique treatment for patients with chronic lymphocytic leukemia (CLL). New Mexico Cancer Center. Invited. Treanda (Bendamustine): A unique treatment for patients with chronic lymphocytic leukemia (CLL). New Mexico Cancer Center. Albuquerque, NM, US.
- 2011. Overview of chronic lymphocytic leukemia (CLL) and Rituxan (Rituximab) for previously untreated and previously treated CD20-positive CLL. Invited. Overview of chronic lymphocytic leukemia (CLL) and Rituxan (Rituximab) for previously untreated and previously treated CD20-positive CLL. Tulsa, OK, US.
- 2011. First-line management strategies with Rituxan (rituximab): Rituxan with CVP for patients with follicular NHL. Rituxan following CVP for patients with low-grade NHL. Rituxan as maintenance therapy following Rituxan with chemotherapy. Cancer Treatment Centers of America at Southwest Regional Medical Center. Invited. First-line management strategies with Rituxan (rituximab): Rituxan with CVP for patients with follicular NHL. Rituxan following CVP for patients with low-grade NHL. Rituxan as maintenance therapy following Rituxan with chemotherapy. Cancer Treatment Centers of America at Southwest Regional Medical Center. Tulsa, OK, US.
- 2011. Conflict of Interest: Issues in Education. Association of Clinical Researchers and Educators (ACRE) 2011 Annual Conference. Invited. Uris Auditorium at Weill Cornell Medical Center. New York, NY, US.
- 2011. Treanda (Bendamustine): A unique treatment for patients with indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within 6 months of a rituximab containing regimen.ION In-Practice Presentation. Invited. Treanda (Bendamustine): A unique treatment for patients with indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within 6 months of a rituximab containing regimen.ION In-Practice Presentation. Pawleys Island, SC, US.
- 2011. Treanda (Bendamustine): A unique treatment for patients with indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within 6 months of a rituximab containing regimen. Invited. Treanda (Bendamustine): A unique treatment for patients with indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within 6 months of a rituximab containing regimen. Long Beach, CA, US.
- 2011. First-line management strategies with Rituxan (rituximab): Rituxan with CVP for patients with follicular NHL. Rituxan following CVP for patients with low-grade NHL. Rituxan as maintenance therapy following Rituxan with chemotherapy. Invited. First-line management strategies with Rituxan (rituximab): Rituxan with CVP for patients with follicular NHL. Rituxan following CVP for patients with low-grade NHL. Rituxan as maintenance therapy following Rituxan with chemotherapy. Athens, GA, US.
- 2011. First-line management strategies with Rituxan (rituximab): Rituxan with CVP for patients with follicular NHL. Rituxan following CVP for patients with low-grade NHL. Rituxan as maintenance therapy following Rituxan with chemotherapy. Invited. First-line management strategies with Rituxan (rituximab): Rituxan with CVP for patients with follicular NHL. Rituxan following CVP for patients with low-grade NHL. Rituxan as maintenance therapy following Rituxan with chemotherapy. Austin, TX, US.
- 2011. First-line management strategies with Rituxan (rituximab): Rituxan with CVP for patients with follicular NHL. Rituxan following CVP for patients with low-grade NHL. Rituxan as maintenance therapy following Rituxan with chemotherapy. Invited. First-line management strategies with Rituxan (rituximab): Rituxan with CVP for patients with follicular NHL. Rituxan following CVP for patients with low-grade NHL. Rituxan as maintenance therapy following Rituxan with chemotherapy. Houston, TX, US.
- 2011. Treanda (Bendamustine): A unique treatment for patients with indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within 6 months of a rituximab containing regimen. Invited. Treanda (Bendamustine): A unique treatment for patients with indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within 6 months of a rituximab containing regimen. Baltimore, MD, US.
- 2011. Treanda (Bendamustine): A unique treatment for patients with chronic lymphocytic leukemia (CLL). Invited. Treanda (Bendamustine): A unique treatment for patients with chronic lymphocytic leukemia (CLL). Glen Burnie, MD, US.
- 2011. Treanda (Bendamustine): A unique treatment for patients with chronic lymphocytic leukemia (CLL). Invited. Treanda (Bendamustine): A unique treatment for patients with chronic lymphocytic leukemia (CLL). Bethesda, MD, US.
- 2011. Treanda (Bendamustine): A unique treatment for patients with chronic lymphocytic leukemia (CLL). Invited. Treanda (Bendamustine): A unique treatment for patients with chronic lymphocytic leukemia (CLL). Oklahoma City, OK, US.
- 2011. Nicholson Integrative Medicine Roundtable Seminar- Complementary and Integrative Medicine in Cancer Care. Invited. UTMB. Galveston, TX, US.
- 2011. Lymphoma and Related Disorders II. DHM Second Year Medical Student Lecture. Invited. Lymphoma and Related Disorders II. DHM Second Year Medical Student Lecture. Galveston, TX, US.
- 2011. Lymphoma and Related Disorders I. DHM Second Year Medical Student Lecture. Invited. Lymphoma and Related Disorders I. DHM Second Year Medical Student Lecture. Galveston, TX, US.
- 2011. Treanda (Bendamustine): A unique treatment for patients with chronic lymphocytic leukemia (CLL). Invited. Treanda (Bendamustine): A unique treatment for patients with chronic lymphocytic leukemia (CLL). Newport Beach, CA, US.
- 2011. First-line management strategies with Rituxan (rituximab): Rituxan with CVP for patients with follicular NHL. Rituxan following CVP for patients with low-grade NHL. Rituxan as maintenance therapy following Rituxan with chemotherapy. Invited. First-line management strategies with Rituxan (rituximab): Rituxan with CVP for patients with follicular NHL. Rituxan following CVP for patients with low-grade NHL. Rituxan as maintenance therapy following Rituxan with chemotherapy. Hershey, PA, US.
- 2011. Treanda (Bendamustine): A unique treatment for patients with indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within 6 months of a rituximab containing regimen. South Texas Institute of Cancer. Invited. Treanda (Bendamustine): A unique treatment for patients with indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within 6 months of a rituximab containing regimen. South Texas Institute of Cancer. Corpus Christi, TX, US.
- 2011. First-line management strategies with Rituxan (rituximab): Rituxan with CVP for patients with follicular NHL. Rituxan following CVP for patients with low-grade NHL. Rituxan as maintenance therapy following Rituxan with chemotherapy. Invited. First-line management strategies with Rituxan (rituximab): Rituxan with CVP for patients with follicular NHL. Rituxan following CVP for patients with low-grade NHL. Rituxan as maintenance therapy following Rituxan with chemotherapy. Effingham, IL, US.
- 2011. Review of Oncology and Tumor Biology. Invited. UTMB School of Medicine. Galveston, TX, US.
- 2011. Post induction therapy: A physician’s perspective on EORTC, PRIMA and ECOG 1496. Invited. Genentech National Sales Meeting. Las Vegas, NV, US.
- 2011. A thought leader’s perspective on maintenance Rituxan referencing EORTC, PRIMA and ECOG 1496 trials. Rituxan Core Hematology Training. Invited. 2011 Hematology SAM Meeting. Phoenix, AZ, US.
- 2010. Problem Based Learning: Rituxan in previously untreated and previously treated follicular, CD20- positive, B-Cell non-Hodgkin lymphoma. Invited. Problem Based Learning: Rituxan in previously untreated and previously treated follicular, CD20- positive, B-Cell non-Hodgkin lymphoma. Cherry Hill, NJ, US.
- 2010. Problem Based Learning: Rituxan in previously untreated and previously treated follicular, CD20- positive, B-Cell non-Hodgkin lymphoma. Invited. Problem Based Learning: Rituxan in previously untreated and previously treated follicular, CD20- positive, B-Cell non-Hodgkin lymphoma. Oklahoma City, OK, US.
- 2010. Treanda (Bendamustine) in rituximab relapsed or refractory follicular B-cell non-Hodgkin lymphoma. Invited. Treanda (Bendamustine) in rituximab relapsed or refractory follicular B-cell non-Hodgkin lymphoma. Beaumont, TX, US.
- 2010. Overview of chronic lymphocytic leukemia (CLL) and Rituxan (Rituximab) for previously untreated and previously treated CD20-positive CLL. Cancer Centers of Southwest Oklahoma. Invited. Overview of chronic lymphocytic leukemia (CLL) and Rituxan (Rituximab) for previously untreated and previously treated CD20-positive CLL. Cancer Centers of Southwest Oklahoma. Lawton, OK, US.
- 2010. Treanda (Bendamustine) in rituximab relapsed or refractory follicular B-cell non-Hodgkin lymphoma. Broome Oncology. Invited. Treanda (Bendamustine) in rituximab relapsed or refractory follicular B-cell non-Hodgkin lymphoma. Broome Oncology. Johnson City, NY, US.
- 2010. Treanda (Bendamustine) in rituximab relapsed or refractory follicular B-cell non-Hodgkin lymphoma. Invited. Treanda (Bendamustine) in rituximab relapsed or refractory follicular B-cell non-Hodgkin lymphoma. Charleston, SC, US.
- 2010. Rationale for Screening and Prevention in Common Adult Cancers. Invited. Galveston Rotary Club. Galveston, TX, US.
- 2010. Treanda (Bendamustine) in rituximab relapsed or refractory follicular B-cell non-Hodgkin lymphoma. Invited. Treanda (Bendamustine) in rituximab relapsed or refractory follicular B-cell non-Hodgkin lymphoma. Houston, TX, US.
- 2010. Overview of chronic lymphocytic leukemia (CLL) and Rituxan (Rituximab) for previously untreated and previously treated CD20-positive CLL. Invited. Overview of chronic lymphocytic leukemia (CLL) and Rituxan (Rituximab) for previously untreated and previously treated CD20-positive CLL. Dallas, TX, US.
- 2010. Moderator for 2010 Rituxan Advisory Initiative on Chronic Lymphocytic Leukemia. Invited. Moderator for 2010 Rituxan Advisory Initiative on Chronic Lymphocytic Leukemia. Dallas, TX, US.
- 2010. Overview of chronic lymphocytic leukemia (CLL) and Rituxan (Rituximab) for previously untreated and previously treated CD20-positive CLL. Invited. Overview of chronic lymphocytic leukemia (CLL) and Rituxan (Rituximab) for previously untreated and previously treated CD20-positive CLL. Fort Worth, TX, US.
- 2010. Lymphoma and Related Disorders I. DHM Second Year Medical Student Lecture. Invited. UTMB School of Medicine. Galveston, TX, US.
- 2010. Rituxan (Rituximab) plus CHOP or other anthracycline-based chemotherapy for the management of patients with diffuse large B-cell lymphoma. Invited. Rituxan (Rituximab) plus CHOP or other anthracycline-based chemotherapy for the management of patients with diffuse large B-cell lymphoma. Columbia, SC, US.
- 2010. Overview of chronic lymphocytic leukemia (CLL) and Rituxan (Rituximab) for previously untreated and previously treated CD20-positive CLL. Invited. Overview of chronic lymphocytic leukemia (CLL) and Rituxan (Rituximab) for previously untreated and previously treated CD20-positive CLL. Hutchinson, KS, US.
- 2010. Academia and Industry. Invited. UTMB Comprehensive Cancer Center Grand Rounds. Galveston, TX, US.
- 2009. Rituxan (Rituximab) Therapy for the Front Line Treatment of Low-grade or Follicular, CD20- Positive, B-Cell Non-Hodgkin Lymphoma. Mitchell Cancer Center. Invited. Mitchell Cancer Center. Mobile, AL, US.
- 2009. Rituxan (Rituximab) Therapy for the Front Line Treatment of Low-grade or Follicular, CD20- Positive, B-Cell Non-Hodgkin Lymphoma. Invited. Rituxan (Rituximab) Therapy for the Front Line Treatment of Low-grade or Follicular, CD20- Positive, B-Cell Non-Hodgkin Lymphoma. Dallas, TX, US.
- 2009. Treanda (Bendamustine) in Rituximab Relapsed or Refractory Follicular B-cell non-Hodgkin Lymphoma. Invited. Treanda (Bendamustine) in Rituximab Relapsed or Refractory Follicular B-cell non-Hodgkin Lymphoma. Oxnard, CA, US.
- 2009. Session Moderator for Value of Promotional Speaking to Speakers and Listeners. Invited. Session Moderator for Value of Promotional Speaking to Speakers and Listeners. Boston, MA, US.
- 2009. Rituxan (Rituximab) Therapy for the Front Line Treatment of Low-grade or Follicular, CD20- Positive, B-Cell Non-Hodgkin Lymphoma. Invited. Desert Hematology Oncology Medical Group. Rancho Mirage, CA, US.
- 2009. Rituxan (Rituximab) Therapy for the Front Line Treatment of Low-grade or Follicular, CD20- Positive, B-Cell Non-Hodgkin Lymphoma. Invited. Birmingham Hematology and Oncology Associates, LLC. Birmingham, AL, US.
- 2008. Rituxan (Rituximab) Therapy for the Front Line Treatment of Low-grade or Follicular, CD20-Positive, B-Cell Non-Hodgkin Lymphoma. Invited. Rituxan (Rituximab) Therapy for the Front Line Treatment of Low-grade or Follicular, CD20-Positive, B-Cell Non-Hodgkin Lymphoma. Albany, GA, US.
- 2008. Rituxan (Rituximab): FDA approved Indications in CD20-Positive, B-Cell Non-Hodgkin Lymphoma. Invited. Rituxan (Rituximab): FDA approved Indications in CD20-Positive, B-Cell Non-Hodgkin Lymphoma. San Antonio, TX, US.
- 2008. Rituxan (Rituximab) Therapy for the Front Line Treatment of Low-grade or Follicular, CD20-Positive, B-Cell Non-Hodgkin Lymphoma. Invited. Rituxan (Rituximab) Therapy for the Front Line Treatment of Low-grade or Follicular, CD20-Positive, B-Cell Non-Hodgkin Lymphoma. Altamont Springs, FL, US.
- 2008. Rituxan (Rituximab): FDA approved Indications in CD20-Positive, B-Cell Non-Hodgkin Lymphoma. Invited. Rituxan (Rituximab): FDA approved Indications in CD20-Positive, B-Cell Non-Hodgkin Lymphoma. Augusta, GA, US.
- 2007. Malignant Melanoma - Current Treatment Options. Gynecology Oncology Fellowship Didactic Lecture Series. Invited. Malignant Melanoma - Current Treatment Options. Gynecology Oncology Fellowship Didactic Lecture Series. Galveston, TX, US.
- 2006. Rituxan (Rituximab) Therapy for the First-Line Treatment of Diffuse Large B-Cell, CD20-Positive, B-Cell Non Hodgkin’s Lymphoma (NHL) in Combination with CHOP or other Anthracycline-Based Chemotherapy Regimens. Invited. Rituxan (Rituximab) Therapy for the First-Line Treatment of Diffuse Large B-Cell, CD20-Positive, B-Cell Non Hodgkin’s Lymphoma (NHL) in Combination with CHOP or other Anthracycline-Based Chemotherapy Regimens. Houston, TX, US.
- 2006. Rituxan Advisory Initiative. Invited. Rituxan Advisory Initiative. Dallas, TX, US.
- 2006. Rituxan (Rituximab) Therapy for the Treatment of Relapsed or Refractory, Low-Grade or Follicular, CD20-Positive, B-Cell Non Hodgkin Lymphoma (NHL). Invited. Rituxan (Rituximab) Therapy for the Treatment of Relapsed or Refractory, Low-Grade or Follicular, CD20-Positive, B-Cell Non Hodgkin Lymphoma (NHL). Olathe, KS, US.
- 2006. Rituxan (Rituximab) Therapy for the Treatment of Non-Hodgkin Lymphoma. Invited. Rituxan (Rituximab) Therapy for the Treatment of Non-Hodgkin Lymphoma. Duluth, MN, US.
- 2006. Rituxan (Rituximab) Therapy for the Treatment of Non-Hodgkin Lymphoma. Invited. Rituxan (Rituximab) Therapy for the Treatment of Non-Hodgkin Lymphoma. Council Bluffs, IA, US.
- 2006. Rituxan (Rituximab) Therapy for the Treatment of Non-Hodgkin Lymphoma. Invited. Rituxan (Rituximab) Therapy for the Treatment of Non-Hodgkin Lymphoma. Tyler, TX, US.
- 2005. Rituxan (Rituximab) Therapy for the Treatment of Non-Hodgkin Lymphoma. Invited. Rituxan (Rituximab) Therapy for the Treatment of Non-Hodgkin Lymphoma. Austell, GA, US.
- 2005. Moderator for 2005 Rituxan Consultant Initiative. Invited. Sofitel Water Tower. Chicago, IL, US.
- 2005. Update on Melanoma. The 12th Annual Essentials in Internal Medicine: Update on Principles and Practice. Invited. UTMB: Moody Gardens Hotel. Galveston, TX, US.
- 2005. Rituxan in Indolent Lymphoma. Invited. The University of Texas Medical Branch School of Medicine. Galveston, TX, US.
- 2005. Preferred Treatment and Management Options. Hoag Cancer Center. Invited. Hoag Cancer Center. Newport Beach, CA, US.
- 2003. Overview of Cytoprotection with Amifostine. Invited. University of North Texas Health Science Center. Fort Worth, TX, US.
- 2002. Adjuvant Therapy of Melanoma with Interferon. Invited. M.D. Anderson. Steamboat Springs, CO, US.
- 1997. Adjuvant Therapy of Stage III Melanoma. Lymphatic Mapping and Sentinel Lymph Node Biopsy in Breast Cancer and Melanoma. Invited. The University of Texas Southwestern Medical Center. Dallas, TX, US.
- 1997. Renal Cell Carcinoma. Invited. Medical University of South Carolina. Charleston, SC, US.
- 1997. Melanoma. Invited. St. Francis Cabrini Hospital Cancer Center. New York, NY, US.
- 1997. Melanoma. Invited. University of Texas, Southwestern School of Medicine Parkland Memorial Hospital. Dallas, TX, US.
- 1996. Melanoma. Invited. Texas Tech University Health Sciences Center at Amarillo. Amarillo, TX, US.
- 1996. Adjuvant Therapy of High Risk Melanoma. Invited. Terrebonne General Hospital. Houma, LA, US.
- 1996. Melanoma. Invited. Wilford Hall Medical Center. San Antonio, TX, US.
- 1995. Renal Cell Carcinoma. Invited. Renal Cell Carcinoma. Bay Pines, FL, US.
- 1995. Biologic Therapy of Cancer. Invited. Charleston Area Medical Center. Charleston, WV, US.
- 1995. Interferon: Side Effects and Their Management. Invited. Interferon: Side Effects and Their Management. Rancho Mirage, CA, US.
- 1995. Overview of Interferon in Cancer. Invited. West Florida Hospital. Pensacola, FL, US.
- 1995. Overview of Interferon in Cancer. Invited. Olive View Medical Center. Sylmar, CA, US.
- 1994. Biologic Therapy of Solid Tumors. Invited. Louisiana State University Medical Center. Shreveport, LA, US.
- 1994. Treatment of Malignant Effusions with Intracavitary Interferon. Invited. Columbia Presbyterian Hospital. New York, NY, US.
- 1994. Biologic Therapy of Renal Cell Carcinoma. Invited. Lennox Hill Hospital. New York, NY, US.
- 1993. Biologic Therapy of Renal Cell Carcinoma. Invited. The New York Hospital-Cornell Medical Center. New York, NY, US.
- 1993. Interleukin-4 in Cancer and Bone Marrow Failure. Invited. Mt. Sinai Medical Center Chemotherapy Foundation Symposium. New York, NY, US.
- 1993. Biotherapy of Cancer. Invited. George Washington University Medical Center. Arlington, VA, US.
- 1993. Multimodality Therapy of Rectal Cancer. Invited. Maine Medical Center. Portland, ME, US.
- 1993. Novel Uses of Interferon. Invited. Medical Oncology Association of Southern California. La Jolla, CA, US.
International Presentations
- 2014. Granix (G-CSF). Invited. ASCO. Chicago, US.
- 2014. Post-induction Rituxan use in indolent non-Hodgkin lymphoma and Gazyva first-line treatment in chronic lymphocytic leukemia: Real world considerations for both patients and physicians in a world with options. Invited. Post-induction Rituxan use in indolent non-Hodgkin lymphoma and Gazyva first-line treatment in chronic lymphocytic leukemia: Real world considerations for both patients and physicians in a world with options. Las Vegas, US.
- 1995. Adjuvant Therapy of Gastric and Colorectal Cancer. Invited. National Institute for the Study and Cure of Cancer. Naples, IT.
- 1993. Interferon-in the Treatment of Solid Tumors. Invited. Interferon-in the Treatment of Solid Tumors. Jerusalem, IL.
- New Therapeutic Options for Interferon. Invited. Innovations in Cancer Management. Istanbul, TR.
Formal Peers
- 2015. Molecular Basis of Hematologic Malignancies. Invited. Grand Rapids. Grand Rapids, MI, US.
- 2015. Academia and Industry. Invited. John P. McGovern Academy of Oslerian Medicine at UTMB. Galveston, TX, US.
- 2011. Update on Non-Hodgkin Lymphoma. Invited. Texas Club of Internists Annual Meeting. Galveston, TX, US.
- 2011. Review of Oncology and Tumor Biology. Invited. UTMB School of Medicine. Galveston, TX, US.
- 1998. Interferon in Renal Cell Carcinoma. Invited. University of Texas Medical Branch. Galveston, TX, US.
- 1993. Novel Uses of Interferon. Invited. Newport Beach, CA, US.
- 1993. Novel Uses of Interferon. Invited. Medical Oncology Association of Southern California. La Jolla, CA, US.
- 1993. Biologic Based Therapy of Renal Cell Carcinoma. Invited. Southern Florida Society of Medical Oncology. Fort Lauderdale, FL, US.
- 1992. 5-FU plus Interferon in Solid Tumors. Invited. Kuakini Medical Center. Honolulu, HI, US.
- 1992. Treatment Update for Colorectal/GI Cancers. Invited. Cancer Center of Hawaii. Honolulu, HI, US.
- 1991. 5-FU plus Interferon in Colon Cancer. Invited. University of California at Irvine. Irvine, CA, US.
- 1991. 5-FU plus Interferon in Solid Tumors. Invited. University of Toronto. Toronto, CA.
- 1991. Update on Interferon in Cancer. Invited. Santa Barbara Cancer Foundation. Dearborn, MI, US.
- 1991. Recombinant Interleukin-2 plus Recombinant Interferon in Solid Tumors. Invited. 49th Nordic Conference of Medicine and Radiology. Tampere, FI.
- 1991. Update on Therapy with Interferon. Invited. Children’s Hospital of San Francisco. San Francisco, CA, US.
- 1991. Interferon, Interleukin-2, and Interleukin-4 in Solid Tumors. Invited. Ottawa General Hospital Regional Cancer Center. Ottawa, CA.
- 1991. The Role of Biological Response Modifiers in Solid Tumors. Invited. Royal Victoria Hospital. Montreal, CA.
- 1991. Placement of Interferon in Oncology. Invited. St. Vincent’s Hospital. Santa Fe, NM, US.
- 1991. Interferon-+ IL-2 in the Treatment of Renal Cell Carcinoma and Interferon + 5-FU in the Treatment of Solid Tumors. Invited. Cleveland Clinic. Cleveland, OH, US.
- 1990. Interferon in Malignant Melanoma Symposium: Interferon in the 90’s: Decade of Decision. Invited. University of Arizona and University of North Carolina Chapel Hill. Phoenix, AZ, US.
- 1990. Interferon-+ 5-FU in the Treatment of Solid Tumors. Invited. Phoenix Oncology Society. Phoenix, AZ, US.
- 1990. Overview of Interferons. Invited. Veterans Administration Medical Center. Hampton, VA, US.
- 1990. Interferon + 5-FU in the Treatment of Solid Tumors Symposium: Update on Medical Therapy of Gastrointestinal Tumors. Invited. University of Innsbruck. Innsbruck, AT.
- 1990. Interferons and Interleukins: Therapy into the 90's. Invited. Children's Hospital of San Francisco. San Francisco, CA, US.
- 1989. Overview of Biologic Therapy in Cancer. Invited. Humana Hospital, Sunrise. Las Vegas, NV, US.
- 1989. Interleukin-2 Based Therapy of Solid Tumors. Invited. Florida Society of Clinical Oncology and Florida Radiological Society. Orlando, FL, US.
- 1989. Biologic Therapy of Cancer. Invited. University of Alabama. Birmingham, AL, US.
- 1989. Biologic Based Therapy of Melanoma. Invited. The Bowman Gray School of Medicine Wake Forest Universit. Winston-Salem, NC, US.
- 1989. Interferon and Biologic Response Modifiers in Melanoma Symposium: Advances in the Biological Therapy of Cancer. Invited. University of North Carolina at Chapel Hill. Tampa Bay, FL, US.
- 1989. Experience with Interleukin-2 Symposium: Innovations in Urologic Practice. Invited. Baylor College of Medicine. Houston, TX, US.
- 1988. Update on Studies of Interferon-+ Interleukin-2. Invited. MD Anderson ASCO CCOP. New Orleans, LA, US.
- 1987. An Overview of Interferon in Treatment of Malignancies. Invited. Mercy San Juan Hospital. Sacramento, CA, US.
- 1987. Interferon Therapy of Malignant Melanoma Symposium: Current Role and Future Direction of Interferon Therapy for Dermatologic Neoplasia. Invited. Stanford University Medical Center. Palo Alto, CA, US.
- 1987. Biologic Based Therapy of Cancer and Intraperitoneal Therapy of Ovarian Cancer. Invited. Sutter Memorial Hospital. Sacramento, CA, US.
Grant & Contract Support
| Title: | A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy |
| Funding Source: | NRG Oncology Group |
| Role: | PI |
| Title: | A Phase II Randomized, Multicenter Study of Treatment-free Remission in Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Patients who Achieve and Sustain MR4.5 after Switching to Nilotinib |
| Funding Source: | Novartis |
| Role: | PI |
| Title: | Phase II Randomized Trial of Adjuvant Radiotherapy with or without Cisplatin for p53 Mutated, Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) |
| Funding Source: | NRG Oncology Group |
| Role: | Collaborator |
| Title: | A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET) |
| Funding Source: | Southwest Oncology Group |
| Role: | Collaborator |
| Title: | NO TITLE PROVIDED |
| Funding Source: | Pharmacyclics |
| Role: | PI |
| Title: | Prospective, Non-Interventional Study of Disease Progression and Treatment of Patients with Polycythemia Vera in United States Academic or Community Clinical Practices (Reveal) |
| Funding Source: | Incyte |
| Role: | Collaborator |
| Title: | Safety and Efficacy of Nab-Paclitaxel (ABRAXANE®) in Combination with Carboplatin as First Line Treatment in Elderly Subjects with Advanced Non-Small Cell Lung Cancer (NSCLC): A Phase IV, Randomized, Open-Label, Multicenter Study (ABOUND 70+) |
| Funding Source: | Celgene |
| Role: | Collaborator |
| Title: | Phase II Trial of Everolimus or Everolimus plus Paclitaxel as First-line Therapy in Cisplatin - Ineligible Participants with Advanced Urothelial Carcinoma: Hoosier Oncology Group GU10-147 |
| Funding Source: | Hoosier Oncology Group |
| Role: | Co-I |
| Title: | The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry |
| Funding Source: | Celgene |
| Role: | Collaborator |
| Title: | A Randomized Phase III of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer |
| Funding Source: | National Surgical Adjuvant Breast and Bowel Project |
| Role: | PI |
| Title: | EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study |
| Funding Source: | Southwest Oncology Group |
| Role: | PI |
| Title: | A Prospective Observational Multicenter Cohort Study to Assess the Incidence of Osteonecrosis of the Jaw (ONJ) in Cancer Patients with Bone Metastases Starting Zoledronic Acid Treatment |
| Funding Source: | Southwest Oncology Group |
| Role: | Collaborator |
| Title: | Phase II Randomized Placebo-Controlled Trial of Cisplatin with or without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer |
| Funding Source: | NIH/NCI |
| Role: | PI |
| Title: | A Randomized Phase III Double Blinded Placebo Controlled Trial Of Aspirin as Adjuvant Therapy for Node Positive Her2 Negative Breast Cancer: The ABC Trial |
| Funding Source: | NRG Oncology Group |
| Role: | PI |
| Title: | An Open-label, Multi-center, Expanded Treatment Protocol of Midostaurin (PKC412) in Adult Patients with Newly Diagnosed FMS-like Tyrosine Kinase Receptor (FLT3) Mutated Acute Myeloid Leukemia (AML) who are Eligible for Standard Induction and Consolidation Chemotherapy |
| Funding Source: | Novartis |
| Role: | PI |
| Title: | A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer |
| Funding Source: | NRG Oncology Group |
| Role: | PI |
| Title: | A Phase II, Single arm, Open Label Study of Treatment-free Remission after Achieving Sustained MR4.5 on Nilotinib |
| Funding Source: | Novartis |
| Role: | PI |
| Title: | Connect CLL: The Chronic Lymphocytic Leukemia (CLL) Disease Registry |
| Funding Source: | Celgene |
| Role: | PI |
Patient Reviews
CV information above last modified January 21, 2025